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Macrophage infiltration into tumors has been corre-
lated with poor clinical outcome in multiple cancer
types. Therefore, tools to image tumor-associated
macrophages could be valuable for diagnosis and
prognosis of cancer. Herein, we describe the
synthesis and characterization of a cathepsin
S-directed, quenched activity-based probe (qABP),
BMV083. This probe makes use of an optimized non-
peptidic scaffold leading to enhanced in vivo proper-
ties relative to previously reported peptide-based
probes. In a syngeneic breast cancer model,
BMV083 provides high tumor-specific fluorescence
that can be visualized using noninvasive optical
imaging methods. Furthermore, analysis of probe-
labeled cells demonstrates that the probe primarily
targets macrophages with an M2 phenotype. Thus,
BMV083 is a potential valuable in vivo reporter for
tumor-associated macrophages that could greatly
facilitate the future studies of macrophage function
in the process of tumorigenesis.
INTRODUCTION
The cysteine cathepsin family contains 11 members that play
important roles in protein breakdown in the lysosome (Turk
et al., 2001). Several family members have also been shown to
play functional roles in the onset and progression of diverse
diseases, ranging from Alzheimer’s disease to cancer (Conus
and Simon, 2010; Mohamed and Sloane, 2006; Mueller-Steiner
et al., 2006; Reiser et al., 2010). Because the activity of these
proteases is highly regulated and dependent on posttransla-
tional maturation of the proenzyme, tools that can report on their
activity levels have been essential to understanding their biolog-Chemistry & Biology 19,ical function in disease pathology. In particular, a number of
activity-based probes (ABPs) have been developed that allow
the direct profiling of cysteine cathepsin activity levels in vivo.
Recently, we developed a near-infrared fluorophore-labeled
quenched ABP (NIRF qABP), GB137, containing a peptide
recognition scaffold linked to an acyloxymethyl ketone (AOMK)
electrophile (Blum et al., 2007). This intrinsically nonfluorescent
probe produces a fluorescent signal upon nucleophilic displace-
ment of the quencher group by the active site cysteine of the
proteolytically active cysteine cathepsin (Figure 1A). Because
high levels of cysteine cathepsin activity are associated with
many tumor types, the probe can be used for direct noninvasive
optical imaging applications. Furthermore, because the probes
are activity dependent, they can also be used to noninvasively
measure the efficacy of small-molecule therapeutics. In contrast
to fluorogenic cathepsin substrates that have also been
successfully used for live animal imaging experiments (Gounaris
et al., 2008; Mahmood and Weissleder, 2003), with the most
recent addition being a cathepsin S-selective substrate (Caglic
et al., 2011), the irreversible nature of the ABPs allows subse-
quent downstream identification of the targeted protease and
correlation with histological and cell biological assessments of
the in vivo tumor microenvironment.
The primary in vivo targets of our first-generation qABP were
cathepsin B, S, and L (Blum et al., 2005; Blum et al., 2007).
Although important roles in tumor development have been
described for all three of these cysteine cathepsins (Gocheva
and Joyce, 2007), cathepsins B and L, like most members of
the cysteine cathepsin family, are ubiquitously expressed
(Conus and Simon, 2010). Cathepsin S, however, is most abun-
dantly expressed in antigen-presenting cells (APCs), where it
plays a major role in MHC II antigen presentation (Zavasnik-
Bergant and Turk, 2006). Macrophages are professional APCs
and are, therefore, key players in immunity. They have a variety
of functions depending on their activation state—classically
activated (M1) or alternatively activated (M2). Macrophages
can also be classified into three groups according to their
homeostatic functions: host defense (classically activated619–628, May 25, 2012 ª2012 Elsevier Ltd All rights reserved 619
Figure 1. Nonpeptidic Cysteine Cathepsin Activity-Based Probes
(A) Schematic presentation of the mechanism of action of a quenched ABP.
(B) Structure of the cathepsin S-selective aldehyde and nitrile inhibitors reported by the Ellman laboratory.
(C) Structures of the peptidic activity-based probes GB123 and the quenched GB137 and the nonpeptidic probes BMV011 and the quenched BMV083.
(D) Labeling profile of GB123, BMV011, and BMV083 in living RAW cells. Cells were exposed to the indicated concentrations of probe for 3 hr, before being
harvested, washed, and lysed. Total protein (40 mg) was resolved on 15% SDS-PAGE, and fluorescently labeled proteins were visualized by in-gel fluorescence
scanning.
(E) Labeling profile of BMV083 in living human primary macrophages. Cells were exposed to the indicated concentrations of BMV083 for 3 hr, before being
harvested, washed, and lysed. Total protein (40 mg) was analyzed as described above.
(F) BMV083 labeling of RAW cell lysate (35 mg total protein) at pH 5.5 and 7.0 with indicated concentrations of probe for 1 hr. Labeled proteins were analyzed as
described above.
See also Figures S1, S2, S3, and S4.
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Nonpeptidic Cathepsin S-Directed NIRF qABPmacrophages), wound healing (wound-healing macrophages),
and immune regulation (regulatory macrophages) (Mosser and
Edwards, 2008). However, macrophages display a high degree
of plasticity, and activation states can change in response to
stimuli from their environment. Furthermore, macrophages can
have a blend of characteristics of multiple groups. One such
type of macrophage is the tumor-associated macrophage
(TAM), which displays characteristics of both wound-healing
and regulatory macrophages and plays important roles in tumor-
igenesis by promoting angiogenesis, tumor growth, and inva-
siveness. These macrophages are recruited to the tumor site
and are stimulated by factors in the tumor microenvironment,
including the cytokine IL-4, which induces cysteine cathepsin
activity (Gocheva et al., 2010). In human studies, TAM infiltration620 Chemistry & Biology 19, 619–628, May 25, 2012 ª2012 Elsevierin tumors has been associated with poor prognosis, for example
in high-risk breast cancers (Mukhtar et al., 2011).
The development of imaging tools to identify TAM infiltration in
tumors could lead to clinical applications for the treatment and
prognosis of cancer. Because of its confined expression, probes
that are designed to target cathepsin S are likely to provide
improved contrast for areas with stimulated macrophages
compared tomore broad-spectrum probes that also target other
cysteine cathepsins that have a broader expression profile.
Herein, we describe the synthesis and characterization of a
cathepsin S-directed, nonpeptidic NIRF qABP with improved
in vivo properties relative to previously reported peptide-based
probes.We use this optimized cathepsin S probe for noninvasive
optical imaging of a syngeneic mouse model of breast cancer.Ltd All rights reserved
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Nonpeptidic Cathepsin S-Directed NIRF qABPFluorescence-activated cell sorting (FACS) experiments identi-
fied specific subsets of myeloid-derived cells with an M2macro-
phage phenotype as the in vivo cellular source of cysteine
cathepsin activity responsible for probe fluorescence. These
data demonstrate the potential value of our ABP for the classifi-
cation of tumor-associatedmyeloid derived cells basedon in vivo
protease activity.
RESULTS AND DISCUSSION
Synthesis and In Vitro Characterization of BMV083
We set out to develop ABPs that would have a high degree of
selectivity for cathepsin S that could be used for noninvasive
imaging applications. Furthermore, we aimed to give the next-
generation probe a more druglike, nonpeptidic character to
improve stability, bioavailability, and half-life in circulation. The
Ellman laboratory recently used the substrate activity screening
(SAS) approach to discover 1,4-disubstituted-1,2,3-triazole-
based nonnatural aldehyde and nitrile inhibitors with high
selectivity for cathepsin S over cathepsin B and L (Figure 1B)
(Patterson et al., 2006; Wood et al., 2005). Triazoles, easily
accessible through the Huisgen cycloaddition, have extensively
been used as stable peptide bond mimics because of their
similar electronic and structural characteristics. We therefore
used these nonpeptidic triazole-based inhibitors as a starting
point for design of our cathepsin S-directed ABPs (the synthesis
of ABPs can be found in the Supplemental Information, Figures
S1–S3 available online). To determine the effect of the change
of scaffold, we synthesized the fluorescent ABP BMV011 by re-
placing the norleucine P1 substituent by a lysine side chain to
introduce the Cy5 fluorophore and the reversible electrophile
by the irreversible 2,6-dimethyl benzoic AOMK (Figure 1C). We
compared the labeling profile of BMV011 with that of the
peptide-based probe GB123 (Blum et al., 2007) by exposing
RAW cells (a mouse leukemic macrophage cell line) in culture
to increasing concentrations of the probes. BMV011 and
GB123 showed comparable labeling potency for cathepsin
S (EC50 = 1.0 mM and = 1.3 mM, respectively). However,
the change in probe scaffold reduced labeling of cathepsin
B (EC50(BMV011) = 6.0 mM and EC50(GB123) = 1.6 mM) and
cathepsin L (Figure 1D, top and middle panel), making
BMV011 more selective for cathepsin S. Encouraged by these
results, we synthesized the qABP BMV083, the nonpeptidic
analog of GB137 (Figure 1C). The introduction of the quencher
moiety further reduced the potency for cathepsin B, similar to
the reduction of potency for cathepsin B seen for GB137
compared to GB123. This is probably due to steric hindrance
with the occluding loop in the prime site pocket of cathepsin B.
The primary target of BMV083 in RAW macrophages was
cathepsin S, with a labeling potency similar to that of GB137 (Fig-
ure S4), and only minimal labeling of cathepsin L at high probe
concentrations. Primary human monocyte-derived macro-
phages exposed to increasing concentrations of BMV083
showed a labeling profile similar to that observed in mouse
macrophages, with cathepsin S being the primary target over
cathepsins B and L (Figure 1E). Cathepsin S, in contrast to other
cysteine cathepsin family members, has a wide pH optimum and
is proteolytically active at both acidic and neutral pH (Kirschke
et al., 1989). Consistent with this finding, we observed equalChemistry & Biology 19,labeling of cathepsin S by BMV083 in RAW cell lysate at acidic
or neutral pH, and substantially diminished labeling of cathepsin
B at neutral pH (Figure 1F).
Having determined the cell permeability and labeling speci-
ficity of BMV083, we wanted to visualize the dynamics of
cysteine cathepsin labeling (unquenching) in living cells using
confocal microscopy and correlate this signal with target
labeling as assessed by SDS-PAGE analysis of the cell extracts.
We exposed 4T1 mouse mammary adenocarcinoma cells to
BMV083 and imaged at various time points (Figure 2A). Cy5 fluo-
rescence signal increased over time and was primarily localized
to a vesicular staining pattern. Fluorescent probe signals could
be eliminated by pretreatment of the cells with a pan-cysteine
cathepsin inhibitor (GB111-NH2) (Blum et al., 2007), suggesting
that probe activation was mediated by active cysteine cathepsin
targets. Gel-based analysis of BMV083 labeling over the same
time course showed that the time-dependent increase in Cy5
fluorescence activation correlated with labeling of cathepsin B
and L. Furthermore, inhibition of target labeling by pretreatment
with GB111-NH2 also correlated with loss of imaging signals in
the cells (Figure 2B). In agreement with its expression profile,
no active cathepsin S was labeled in these cancer cells, which
could explain the slow imaging and labeling kinetics.
To determine whether the probe could more effectively target
cells with high cathepsin S levels, we next performed cell-based
imaging studies in primary mouse bone marrow-derived macro-
phages (BMMs; Figures 2C and 2D). We found that in BMMs
BMV083 is more rapidly unquenched compared to the 4T1 cells.
Virtually all of the probe signal in the BMMs could be colocalized
with a marker of lysosomal compartments (Figure 2D). On the
basis of these findings, we wanted to see whether our cathepsin
S-directed probe would be able to selectively label the cathepsin
S-expressing cells in the presence of cells that predominantly
express cathepsins B and L. Therefore, we cocultured BMMs
with 4T1 cancer cells expressing both GFP and luciferase
(4T1-luc-GFP) and imaged after probe treatment. Indeed, probe
labeling was almost exclusively confined to the non-GFP-
expressing BMMs (Figure 2E). Consistent with the imaging
experiment, SDS-PAGE analysis of the labeled cysteine cathep-
sins in the coculture showed an intense fluorescent cathepsin
S signal that was not present in the culture of the 4T1 cells alone
(Figure 2B) and a labeling pattern very similar to that observed in
the RAW mouse macrophage cell line (Figure 1D). Thus, the
majority of labeling is derived from the macrophage population
with only minimal labeling of cat B and L from the tumor cells.
In Vivo Properties of BMV083 in Tumor-Bearing Mice
Having determined the target preference and cell permeability of
BMV083 in vitro, we next set out to establish the in vivo perfor-
mance of the nonpeptidic qABP compared to the original
peptidic GB137.We subcutaneously allografted athymic BALB/c
nude mice with 4T1-luc-GFP cells. When tumors were estab-
lished, we injected two cohorts of tumor-bearing mice via tail
vein with equimolar amounts of either GB137 or BMV083 and
noninvasively imaged the mice for Cy5 fluorescence over time
(Figures 3A and 3B). Images of the whole mice are depicted in
Figure S5A. As reported previously in xenograft tumor models,
GB137 showed specific accumulation in tumors starting at early
time points (Figure 3A) (Blum et al., 2007). The nonpeptidic619–628, May 25, 2012 ª2012 Elsevier Ltd All rights reserved 621
Figure 2. Live-Cell Imaging of Probe Labeling
(A–D) Live-cell confocal microscopy time course of BMV083 cysteine cathepsin labeling. (A) 4T1-luc-GFP cells were exposed to 1 mMBMV083 and imaged over
time. Where indicated, cells were preincubated with the cysteine cathepsin inhibitor GB111-NH2 (5 mM) for 1 hr before addition of probe (scale bar, 10 mm). (B)
4T1-luc-GFP cells were exposed to 1 mM BMV083 and harvested at indicated time points. Total protein (40 mg) was resolved on 15% SDS-PAGE, and
fluorescently labeled proteins were visualized by in-gel fluorescence scanning (MW =molecular weight). (C) Mouse primary bone marrow-derived macrophages
were exposed to 1 mM BMV083 and imaged over time (scale bar, 10 mm). (D) After final time point, lysotracker was added (scale bar, 10 mm).
(E) 4T1-luc-GFP cells and mouse primary bone marrow-derived macrophages (2 to 1 ratio) were cocultured. After 90 hr, the cells were exposed to 1 mMBMV083
for 2 hr. Cells were imaged (red, Cy5 fluorescence; green, GFP; blue, DAPI staining; scale bar, 10 mm) and harvested. Total protein (40 mg) was resolved on 15%
SDS-PAGE, and fluorescently labeled proteins were visualized by in-gel fluorescence scanning.
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Nonpeptidic Cathepsin S-Directed NIRF qABPcounterpart BMV083, however, showed increased tumor-
specific activation of fluorescence, resulting in substantially
better contrast at all time points compared to GB137 (Figures
3A and 3B). The tumor-specific fluorescence intensity for
BMV083, like GB137, peaked around the 4 hr time point (Fig-
ure 3C). Interestingly, unlike the GB137 tumor-specific fluores-
cence, which decreased over time, the BMV083 signal in tumors
remained constant until the end of the time course. This could be
due to enhanced stability of the free probe in vivo, resulting in
extended labeling of newly synthesized pools of cysteine
cathepsin. After the completion of the noninvasive optical
imaging time course, we excised tumors and performed
ex vivo imaging followed by homogenization and analysis of
the fluorescently labeled protein content by SDS-PAGE (Fig-
ure 3D). Here, too, BMV083 had significantly increased overall
cysteine cathepsin labeling compared to GB137. The in vivo
targets for GB137 were primarily cathepsin B (38.0% ± 5.7%
[n = 5]) and L (33.6% ± 2.3% [n = 5]) and, to a lesser extent,
cathepsin S (28.4% ± 1.8% [n = 5]). Although in cultured RAW
cells, BMV083 almost exclusively labels cathepsin S in the
presence of the more abundant cathepsin B (Figure 1D), in vivo622 Chemistry & Biology 19, 619–628, May 25, 2012 ª2012 Elsevierthe primary target for BMV083 was cathepsin S (61.4% ± 5.8%
[n = 5]), with cathepsin B being the secondary target (38.6% ±
5.2% [n = 5]). To determine the overall activity levels of the
cysteine cathepsins in the 4T1 allografted tumors, we labeled
tumor homogenates with the BODIPY TMR-labeled general
cysteine cathepsin probe BMV099 (Figure 3D; for structure and
characterization of BMV099, see Figure S6). Interestingly, this
analysis indicated that the most active cysteine cathepsin in
this tumor model is cathepsin B. Therefore, the relatively higher
level of cathepsin B labeling by BMV083 in this model is likely
because this is the most active cathepsin found in the tumor
tissues. This result also stresses the fact that the selectivity of
any inhibitor or substrate-based reporter highly depends on
the experimental setup and the relative activity levels of other
related (off-)targets in the tissue, cell, or sample being analyzed.
The advantage of ABPs over substrate-based reporters is that
the covalent irreversible nature of the labeling allows for
biochemical validation and characterization of the in vivo
observed probe fluorescence. Therefore, we could correlate
the enhanced labeling signals by BMV083 in the live animals
with whole-tissue fluorescence and relative levels of cysteineLtd All rights reserved
Figure 3. Noninvasive Optical Imaging of Cysteine Cathepsin Activity with Quenched Activity-Based Probes in Tumor-Bearing Mice
(A–C) 4T1-luc-GFP cells were injected subcutaneously on the back of athymic BALB/c nude mice, 8 days before imaging. GB137 or BMV083 (20 nmol) was
injected (intravenous via tail vein), and fluorescent images of the living mice were taken over time. Red arrowheads indicate the tumor. (A) Optimal fluorescence
contrast for individual time points. Maximum and minimum of scale bar depicted below image. (B) Comparison of GB137 and BMV083 fluorescence at fixed
intensity. (C) Time-dependent tumor-specific fluorescence (tumor  background) for BMV083- and GB137-treated mice (n = 5; data represent mean values ±
standard errors).
(D) Ex vivo fluorescence imaging of cross-sections of excised tumors (upper panel). Tumor tissue was homogenized, and 40 mg of total protein was resolved on
15% SDS-PAGE. In vivo fluorescently labeled proteins were visualized by in-gel fluorescence scanning (middle panel). 4T1 tumors were homogenized, and the
active cysteine cathepsins were labeled with BMV099 (1 mM for 1 hr; 80 mg total protein) before the proteins were resolved on 15% SDS-PAGE. Fluorescently
labeled proteins were visualized by in-gel fluorescence scanning (lower panel).
(E) Fluorescence intensity of end point of noninvasive optical imaging (shown in A), ex vivo tumor imaging, and in-gel fluorescence labeling (shown in D). Intensity
relative to BMV083 is depicted (n = 5; data represent mean values ± standard errors).
See also Figures S5 and S6.
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Nonpeptidic Cathepsin S-Directed NIRF qABPcathepsin labeling observed for each probe by SDS-PAGE
(Figure 3E).
The fact that GB137 and BMV083 have similar labeling poten-
cies in vitro, yet the nonpeptidic probe was amore effective label
in vivo, indicates that the nonpeptidic BMV083 has better in vivo
properties compared to the peptidic GB137. Furthermore, liver
and kidney fluorescence and cysteine cathepsin labeling were
very similar for both probes (Figure S5B), indicating that
BMV083might circulate longer before being scavenged by these
organs for clearance.
We next tested BMV083 in a more physiologically relevant
orthotopic mouse breast cancer model. For this model, we
implanted the 4T1 cell line isolated from a spontaneously arising
BALB/c mammary tumor into the mammary fat pad of BALB/c
mice with an intact immune system (Tao et al., 2008). This
is especially important because host-tumor interactions andChemistry & Biology 19,immune cell infiltration in the tumormicroenvironment are impor-
tant factors in tumor development. We implanted 4T1-luc-GFP
cells in the number 2 and 7mammary fat pads, and tumor growth
wasmonitored. We then intraperitoneally injected tumor-bearing
mice with luciferin 10 hr after probe injection followed by imaging
for bioluminescence and probe-derived Cy5 fluorescence (Fig-
ure 4A). The cancer cell-derived luciferase bioluminescence
demarcated the tumor boundaries, and BMV083 activation
was localized to the same area, indicating elevated cysteine
cathepsin activity in the 4T1 tumor microenvironment. Interest-
ingly, compared to the allograft model, fluorescence analysis
of the SDS-PAGE-resolved protein content revealed cathepsin
S as the major in vivo target for BMV083, with only minor labeling
of cathepsin B (Figure 4B; cathepsin S represents 82.0% ± 0.7%
[n = 6] of total labeling intensity). Ex vivo labeling of the active
cysteine cathepsin content in whole tumor homogenates with619–628, May 25, 2012 ª2012 Elsevier Ltd All rights reserved 623
Figure 4. Noninvasive Optical Imaging of Cysteine
Cathepsin Activity in a Syngeneic Orthotopic
Model for Breast Cancer
(A) 4T1-luc-GFP cells were implanted into mammary fat
pad numbers 2 and 7 of female BALB/c mice. On day 15,
BMV083 (20 nmol) was injected (intravenous via tail vein).
Ten hours after injection, the mice were injected with
luciferin (intraperitoneal), and fluorescence and lumines-
cence images of the living mice were taken (top panel,
bright field image). Red arrowheads indicate the tumors;
middle panel, luciferase bioluminescence (Luc); lower
panel, BMV083 signal (Cy5). Ex vivo fluorescence image of
excised tumors is shown.
(B) BMV083 labeling in tumors. The tumors were homog-
enized, and the active cysteine cathepsins were labeled
with BMV099 (1 mM for 1 hr; 40 mg total protein) before the
proteins were resolved on 15% SDS-PAGE. Fluorescently
labeled proteins were visualized by in-gel fluorescence
scanning (top panel, in vivo BMV083 labeling; bottom
panel, ex vivo BMV099 labeling).
(C) In vivo BMV083 distribution. Organs were homoge-
nized, and the active cysteine cathepsins were labeled
with BMV099 (1 mM for 1 hr; 40 mg total protein) before the
proteins were resolved on 15% SDS-PAGE. Fluorescently
labeled proteins were visualized by in-gel fluorescence
scanning. Top: in vivo BMV083 labeling. Bottom: ex vivo
BMV099 labeling; *, autofluorescent band; Tu, tumor; Lv,
liver; Kd, kidney; Sp, spleen; Ht, hart; Lg, lungs; Pn,
pancreas.
See also Figure S6.
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Nonpeptidic Cathepsin S-Directed NIRF qABPBMV099 indicated higher cathepsin S levels relative to cathepsin
B compared to the xenograft model (Figure 3D), which likely
explains why BMV083 labeled primarily cathepsin S in these
tumors (Figure 4B). We performed a biodistribution study
showing that, similar to what has been reported for GB137, the
primary target organs of BMV083 are the liver and spleen (Fig-
ure 4C, upper panel). Ex vivo labeling of the active cysteine
cathepsin content in whole-organ homogenates with BMV099
indicated a high degree of cysteine cathepsin activity in the
organs that are strongly labeled in vivo (Figure 4C). Interestingly,
although there are high levels of cysteine cathepsin activity in the
kidney, it is not effectively targeted by BMV083, indicating
specific partitioning of the probe to certain organs. On a similar
note, the total cysteine cathepsin activity in the tumor was
relatively low; however, the BMV083 signal in tumors is relatively
high, again suggesting partitioning of the probe to specific
tissues.
Cellular Source of BMV083 Labeling in Tumor-Bearing
Mice
Fluorescent ABPs have previously been used to identify the cell
populations within the tumor microenvironment that posses high
levels of cysteine cathepsin activity. For example, fluorescence
microscopy and immunofluorescence identified macrophages
(F4/80+ cells) as the source of cysteine cathepsin activity in the
RIP1-Tag2 mouse model of pancreatic islet cell cancer and in
the MMTV-PyMT mouse model of mammary tumorigenesis
treated with a nonquenched Cy3B labeled-DCG04 analog,
‘‘Cath-ABP’’ (Gocheva et al., 2010). In the same study, tumor-
derived single-cell suspensions were labeled with the fluores-
cent Cath-ABP ex vivo and were analyzed by FACS. Again,
macrophages were identified as the primary source of cysteine624 Chemistry & Biology 19, 619–628, May 25, 2012 ª2012 Elseviercathepsin activity, although a nonmacrophage population was
also found to take up probe. The authors suggested that this
population might include cancer cells. Macrophage activation
is a plastic and dynamic process that may change during
processing of the tissue to generate single-cell suspensions for
labeling and FACS analysis. Labeling of the tumor-derived cells
in vivo is likely to be more physiologically relevant because the
cysteine cathepsin targets are labeled in their native activation
state. We therefore set out to determine the cellular source of
BMV083-derived fluorescence in vivo. Because macrophages
have previously been shown to possess high cysteine cathepsin
activity in the tumor and because the amount of F4/80 expres-
sion is indicative of the macrophage activation state (i.e., M2
type macrophages have high F4/80 expression levels compared
to a lower F4/80 expression on M1 type macrophages) (Fujiu
et al., 2011), we analyzed four populations of cells from the
4T1-luc-GFP syngeneic orthotopic tumors for BMV083 fluores-
cence. These included two populations of F4/80-expressing
cells (F4/80DIM and F4/80HI): cells that did not express GFP
(F4/80GFP) and a population containing the GFP-expressing
tumor cells (F4/80GFP+) (Figure 5A). The F4/80HI population
was responsible for the majority of BMV083 activation, with a
more than 12-fold increase in Cy5 mean fluorescence compared
to vehicle treatment (Figure 5C, gray bars). To confirm this obser-
vation, we isolated the four cell populations in high purity using
flow cytometric cell sorting, lysed equal cell numbers per popu-
lation, and labeled the active cysteine cathepsins ex vivo with
BMV099, followed by gel analysis of in vivo and ex vivo fluores-
cently labeled cysteine cathepsins (Figures 5B and 5C). This
ex vivo labeling confirmed that in vivo probe labeling correlated
with the absolute levels of cysteine cathepsins that were ex-
pressed and active in each cell population and was not the resultLtd All rights reserved
Figure 5. FACS Analysis to Determine Cellular Source of Cysteine Cathepsin Activity in 4T1 Syngeneic Breast Tumors
4T1 cells were implanted intomammary fat pad numbers 2 and 7 of female BALB/cmice. On day 15, BMV083 (20 nmol) was injected (intravenous via tail vein). Ten
hours after injection, tumors were excised.
(A–C) Single-cell suspensions of excised tumors were analyzed by FACS for F4/80 and GFP expression and probe fluorescence. Four populations (F4/80GFP,
F4/80GFP+, F4/80DIM, and F4/80HI) were analyzed and sorted. (A) F4/80 histogram (top panel) and GFP histogram of F4/80 population (lower panel). (B) Equal
cell numbers per population (depicted in A) of vehicle- and BMV083-treatedmice were lysed, and the active cysteine cathepsins were labeled with BMV099 (1 mM
for 1 hr) before the proteins were resolved on 15% SDS-PAGE. Fluorescently labeled proteins were visualized by in-gel fluorescence scanning (top panel, in vivo
BMV083 labeling; lower panel, ex vivo BMV099 labeling; *autofluorescent band). (C) Bar graph of quantification of mean Cy5 fluorescence per population
(depicted in A) and in-gel fluorescence intensity of fluorescently labeled cysteine cathepsins (depicted in B) of vehicle- and BMV083-treated mice.
(D and E) Single-cell suspensions of excised tumors were analyzed by FACS for CD11b, F4/80, MMR, andGr-1 expression and probe fluorescence. (D) FACS plot
and bar graph of mean Cy5 fluorescence of four populations (CD11bF4/80, CD11b+F4/80, CD11b+F4/80DIM, and CD11b+F4/80HI) of vehicle- and BMV083-
treated mice (n = 3; data represent mean values ± standard errors). (E) FACS plot and bar graph of mean Cy5 fluorescence of four populations (MMRGr-1,
MMRGr-1+, MMR+Gr-1, and MMR+Gr-1+) of CD11b+F4/80HI population depicted in (D) (n = 3; data represent mean values ± standard errors).
See also Figure S6.
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Consistent with the overall mean fluorescence levels, the
F4/80HI population showed themost robust labeling of cathepsin
S and, to a lesser extent, cathepsin B, similar to the labeling
profile observed in whole tumor homogenates (Figure 4B).
We observed weaker labeling intensities in the other three
populations, with a slightly more pronounced labeling in the
F4/80DIM population. We also observed a similar trend when
analyzing the same gel for ex vivo BMV099-labeled cysteine
cathepsins, indicating that the highest cysteine cathepsin
activity was in the F4/80HI population. Interestingly, the degree
of F4/80 expression seems to correlate with cysteine cathepsin
activity, which suggests that cysteine cathepsin activity could
be indicative of differences in activation phenotypes of
myeloid-derived cells.
To further investigate which subpopulations of macrophages
have the highest levels of cysteine cathepsin activity in the
tumor microenvironment, we included three markers to identify
the activation state of the labeled myeloid-derived cells.
CD11b+Gr-1+ myeloid-derived suppressor cells (MDSCs) have
been shown to possess high cysteine cathepsin activity in the
APCD468 mouse model of hereditary polyposis (Gounaris et al.,
2008). It is also generally believed that tumor-associated
macrophages (TAMs) possess an M2-like macrophage char-
acter (Mukhtar et al., 2011). We therefore used the macrophageChemistry & Biology 19,mannose receptor (MMR, also known as CD206), which is
elevated in M2 compared to M1 macrophages, as a marker
for the different macrophage populations (Mukhtar et al.,
2011). Because of recent reports concerning the immunoge-
nicity of GFP in BALB/c mice (Bosiljcic et al., 2011), we also im-
planted 4T1 cells lacking the GFP reporter in the number 2 and 7
mammary fat pads of BALB/c mice. We systemically adminis-
tered BMV083 via tail vein injection and excised tumors at
10 hr after injection to generate single-cell suspensions. Consis-
tent with the results in the 4T1-luc-GFP tumors, we observed
the highest levels of probe activation in the F4/80HI cell popula-
tion, as determined by FACS analysis (CD11b+F4/80HI; Fig-
ure 5D). To further characterize the probe-positive cells, we
analyzed the CD11b+F4/80HI population for Gr-1 and MMR
expression (Figure 5E). This analysis determined that BMV083
labeling occurs most predominantly in CD11b+F4/80HI cells
that express MMR. Furthermore, of the CD11b+F4/80HIMMR+
cells, the Gr-1-expressing population showed more than
2-fold higher probe accumulation compared to the Gr-1-nega-
tive population. These data indicate that the CD11b+F4/80HI
MMR+Gr-1+ cells are the major cellular source of cathepsin S
activity in the 4T1 tumor microenvironment. CD11b+F4/80+
Gr-1+ cells in mouse models of cancer have been defined as
myeloid-derived suppressor cells (MDSCs). In response to
TLR4 ligands released from damaged tumor cells, MDSCs619–628, May 25, 2012 ª2012 Elsevier Ltd All rights reserved 625
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vated T cells (Liu et al., 2010).
The data presented here show that the cathepsin S-directed
nonpeptidic NIRF qABP BMV083 has improved in vivo proper-
ties compared to previously developed ABPs. In the syngeneic
4T1 mouse model for breast cancer, this probe primarily reports
on the cysteine cathepsin activity in the tumor-promoting M2
type CD11b+F4/80HIMMR+ macrophages. Of these, the Gr-1
expressing MDSCs constitute the highest degree of probe
activation. Because infiltration of these cell types into the tumor
microenvironment plays an important role in tumor development
and because their occurrence is correlated with poor prognosis
and negative effects on tumor immunotherapy, BMV083 could
be of prognostic value. Furthermore, BMV083 may find applica-
tion in the study of the role of cathepsin S in other diseases, such
as atherosclerosis, inflammatory disorders, and rheumatoid
arthritis (Conus and Simon, 2010; Quillard et al., 2011; Reiser
et al., 2010).
SIGNIFICANCE
Cells of myeloid origin are major contributors to the devel-
opment of many disease states. In vivo imaging tools for
macrophages could greatly facilitate the study of their role
in disease pathology (Quillard et al., 2011). The consequence
of macrophage infiltration in tumor development has been
extensively studied in the last few decades. Some consider
cancer-related inflammation the seventh hallmark of cancer
(Colotta et al., 2009), whereas others consider tumor-
promoting inflammation a hallmark enabling characteristic
(Hanahan and Weinberg, 2011). Regardless, it is clear that
tumor-associated macrophages play important roles in
tumor development and have been shown to promote angio-
genesis, tumor growth, and invasiveness (Mantovani et al.,
2008; Qian and Pollard, 2010). Furthermore, macrophage
infiltration into tumors has been correlatedwith poor clinical
outcome in several cancers (Bingle et al., 2002; Kurahara
et al., 2011; Steidl et al., 2010). The activation state acquired
by the infiltrating macrophage in the tumor microenviron-
ment determines its effect on the tumor. Macrophages
with the M2 phenotype exhibit tumor-promoting character-
istics, whereas M1 macrophages are able to eradicate
tumors. The macrophage activation state is plastic, and
tumor-promoting macrophages can be converted into
tumor-killing M1 macrophages, for example, by local treat-
ment with granulocyte macrophage colony-stimulating
factor (Eubank et al., 2009). Noninvasive imaging tools that
report on the tumor-promoting M2 type tumor-associated
macrophage content could therefore be of prognostic value.
This manuscript presents the synthesis and characteriza-
tion of BMV083, a nonpeptidic cathepsin S-directed NIRF
qABP. This probe shows improved in vivo properties
compared to our previous generation of peptidic quenched
probes, with higher tumor-specific fluorescence in noninva-
sive optical imaging experiments. Furthermore, the primary
cellular source of probe labeling in the tumor was deter-
mined to be macrophages with an M2 phenotype, making
BMV083 a potential in vivo reporter for tumor-associated
macrophages that primarily promote tumor growth.626 Chemistry & Biology 19, 619–628, May 25, 2012 ª2012 ElsevierEXPERIMENTAL PROCEDURES
General
All resins and reagents were purchased from commercial suppliers and used
without further purifications. All solvents used were HPLC grade. All water-
sensitive reactions were preformed in anhydrous solvents under positive
pressure of argon. Reactions were analyzed by LC-MS using an API 150EX
single-quadrupole mass spectrometer (Applied Biosystems). Reverse-phase
HPLC was conducted with an A˚KTA explorer 100 (Amersham Pharmacia
Biotech) using C18 columns. NMR spectra were recorded on a Varian
400 MHz (400/100) or a Varian Inova 600 MHz (600/125 MHz) equipped with
a pulsed field gradient accessory. Chemical shifts are given in ppm (d) relative
to tetramethylsilane as an internal standard. Coupling constants are given in
Hz. Fluorescent gels were scanned using a Typhoon 9400 flatbed laser
scanner (GE Healthcare). Statistical analysis was performed using Microsoft
Excel, and s.e.m. was calculated by dividing the s.d. by the square root of n.
Fluorescent images were acquired on a Zeiss Axiovert 200 M inverted micro-
scope equipped with a 103, 403, and 633 objective (Carl Zeiss). Slidebook
software was used to control themicroscope and camera and for data analysis
(Intelligent Imaging Innovations).
ABP Synthesis
For the synthesis and characterization of BMV011, BMV083, and BMV099 see
the Supplemental Information.
Cell Culture and Labeling of Living Cells
RAW cells were cultured in DMEM (GIBCO) supplemented with 10% fetal
bovine serum (FBS; GIBCO), 100 U/ml penicillin, and 100 mg/ml streptomycin
(GIBCO). 4T1 cells (ATCC) and 4T1-luc-GFP cells were cultured in RPMI
(GIBCO) supplemented with 10% FBS (GIBCO), 100 U/ml penicillin, and
100 mg/ml streptomycin (GIBCO). Primary mouse bone marrow-derived
macrophages (BMDMs) were isolated and cultured as previously described
(Broz et al., 2010). Briefly, bone marrow was isolated from femurs of
6–8-week-old C57BL/6 mice (The Jackson Laboratory, Bar Harbor, ME).
BMDMs were differentiated in DMEM (GIBCO) with 10% FBS and 10%
MCSF-containing cell supernatant for 6 days. The cells were then frozen in
FBS with 10% DMSO and thawed prior to use. All cells were cultured in
a 5% CO2 humidified incubator at 37
C. Cocultures of 4T1-luc-GFP cells
and BMDMs were established by seeding cells in a 2 to 1 ratio and culture
in DMEM supplemented 10% heat-inactivated FBS (GIBCO), 100 U/ml
penicillin, and 100 mg/ml streptomycin (GIBCO) for 90 hr. For the derivation
of primary human macrophages, leukocyte reduction system chambers
were obtained from anonymous blood donations at the Stanford Blood
Center. Peripheral blood mononuclear cells were isolated by Ficoll gradient
centrifugation, and then monocytes were purified on an AutoMACS (Miltenyi)
by positive selection using CD14 microbeads (Miltenyi). Monocytes were
differentiated to macrophages by culturing for 9 days in Iscove’s Modified
Dulbecco’s Medium supplemented with 10% AB human serum (Invitrogen),
100 U/ml penicillin, and 100 mg/ml streptomycin (Invitrogen). For intact cell
labeling, cells were exposed to probe or inhibitor (1 hr preincubation) where
indicated (10003 in DMSO) for the indicated times. The cells were harvested,
washed with PBS, resuspended in hypotonic lysis buffer (50 mM PIPES
[pH 7.4], 10 mM KCl, 5 mM MgCl2, 2 mM EDTA, 4 mM DTT, and 1%
NP-40), put on ice for 15 min, and centrifuged at 4C, and supernatants
were collected. Total protein (40 mg) was denatured with SDS-sample buffer
and resolved by SDS-PAGE (15%), and labeled proteases were visualized by
scanning the gel with a Typhoon imager (GE Healthcare). Labeling intensities
were quantified using Image J software. For lysate labeling of active cysteine
cathepsins, cells were lysed in citrate buffer (50 mM citrate [pH 5.5 or
pH 7.0], 5 mM DDT, 0.5% CHAPS, and 0.1% Triton X). Total protein (35 or
40 mg) was labeled with the indicated probe at indicated concentration for
1 hr at 37C before analysis as described above. For live cell confocal
microscopy, cells were seeded in an 8 well Lab-Tek chambered coverglass
system.
Animal Models
All animal care and experimentation was conducted in accord with current
National Institutes of Health and Stanford University Institutional AnimalLtd All rights reserved
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Nonpeptidic Cathepsin S-Directed NIRF qABPCare and Use Committee guidelines. For the 4T1 allograft model, female
athymic nude mice (nu/nu) (6–8 weeks old, Charles River Laboratories)
were injected subcutaneously with 3 3 106 4T1-luc-GFP cells in PBS under
isoflurane anesthesia, and tumor growth was monitored. On day 8, GB137
or BMV083 (20 nmol; 0.8 nmol g1) was administered via tail vein in 100 ml
volume (60% DMSO in PBS). After injection, mice were imaged noninvasively
at indicated time points using an IVIS 100 system. After the last time point,
the mice were anesthetized with isofluorane and killed by cervical dislocation.
Tumors were removed and imaged ex vivo using an FMT 2500 (Perkin Elmer),
and the tissue was homogenized in muscle lysis buffer (1% Triton X-100,
0.1% SDS, and 0.5% sodium deoxycholate in PBS [pH 7.4]). Proteins
(40 mg) were resolved by SDS-PAGE (15%), and labeled proteases were visu-
alized by scanning the gel with a Typhoon imager (GE Healthcare). Labeling
intensities were quantified using Image J software. For the orthotopic mouse
breast cancer model, female BALB/c mice (6–8 weeks old, The Jackson
Laboratory) were injected in the fat pad numbers 2 and 7 with 1 3 105
4T1-luc-GFP or 4T1 cells (ATCC) in PBS, and tumor growth was monitored.
On day 15, the mice were injected with BMV083 and analyzed as described
above. For ex vivo labeling of active cysteine cathepsins, tissues were
removed and homogenized in citrate buffer (50 mM Citrate [pH 5.5], 5 mM
DDT, 0.5% CHAPS, and 0.1% Triton X). Total protein (40 mg) was labeled
with BMV099 (1 mM final concentration) for 1 hr at 37C before analysis as
described above.Antibody Staining and Flow Cytometry
The tumor tissue was dissected from the mouse, sliced into 1–2 mm3 pieces
with a razor blade, and digested at 37C for approximately 2 hr, with frequent
pipetting in Advanced DMEM/F12 (Invitrogen) with 2 mM Glutamax (Invitro-
gen), 120 mg/ml penicillin, 100 mg/ml streptomycin, and 0.25 mg/ml amphoter-
icin-B (PSA), with 200 U/ml Collagenase type III (Worthington, Lakewood, NJ)
and 100 U/ml DNase I (Worthington). After the digestion reached completion,
cells were filtered with 40 mm nylon mesh (BD Biosciences), washed, and
resuspended at a density of 10 3 106 cells/ml in cold HBBS (Invitrogen) with
PSA and 2% heat inactivated fetal calf serum. To reduce nonspecific
binding, cells suspended in staining buffer were blocked on ice for 10 min
with 10 mg/ml rat IgG (Sigma) at 1:1000. Cells were then stained, in the
dark, on ice for 30 min with optimal antibodies concentrations, which was
determined by titration experiments. Antibodies used include PE-Cy7 anti-
mouse F4/80 (BM8), PE-Cy5 anti-mouse CD11b (M1/70) (ebioscience), FITC
anti-mouse MMR (C068C2), and PE anti-mouse Gr-1 (RB6-8C5) (BioLegend).
Flow cytometry was performed with a BD FacsAria II with FacsDiva software.
Data analysis was performed using Flowjo. For all experiments, side scatter
and forward scatter profiles (area and width) were used to eliminate debris
and cell doublets. Dead cells were eliminated by excluding DAPI+ cells (Molec-
ular Probes).SUPPLEMENTAL INFORMATION
Supplemental Information includes six figures and can be found with this
article online at doi:10.1016/j.chembiol.2012.03.012.ACKNOWLEDGMENTS
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